Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs.

Rodby R, Umanath K, Niecestro R, Jackson JH, Sika M, Lewis JB, Dwyer JP, Collaborative Study Group
Expert Rev Pharmacoecon Outcomes Res. 2015 15 (3): 545-50

PMID: 25495878 · DOI:10.1586/14737167.2015.995169

BACKGROUND - Ferric citrate (FC) is a new phosphorus binder shown to increase serum iron stores while reducing intravenous iron and erythropoiesis-stimulating agent usage. Such reductions could lower hospitalization rates and associated costs.

METHODS - Hospitalizations during a Phase III trial were compared between FC and active control (AC). Hospitalization costs were estimated using the 2013 US Renal Data System Annual Data Report.

RESULTS - 34.6% of FC patients were hospitalized at least once versus 45.6% of the AC group (risk reduction 24.2%; p = 0.02). There were 181 unique hospitalizations in the FC group versus 239 in the AC group, for a difference of 58 hospitalizations. Total potential savings was US$ 867,622 in hospitalization costs in the FC group. If the hospitalization reduction in our study was applied to the general end-stage renal disease population, this could translate into a savings of US$ 3002/patient/year.

CONCLUSIONS - Patients receiving FC experienced fewer hospitalizations with the potential for significant savings.

MeSH Terms (10)

Adult Chelating Agents Cost Savings Ferric Compounds Hospital Costs Hospitalization Humans Kidney Failure, Chronic Phosphorus Renal Dialysis

Connections (1)

This publication is referenced by other Labnodes entities: